**Name of Journal:** ***World Journal of Gastrointestinal Oncology***

**Manuscript NO:** **30870**

**Manuscript Type: Minireviews**

**Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology**

Kang BW *et al*. Tumor-infiltrating lymphocytes in gastric cancer

**Byung Woog Kang, Jong Gwang Kim, In Hee Lee, Han Ik Bae, An Na Seo**

**Byung Woog Kang, Jong Gwang Kim In Hee Lee,** Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41404, South Korea

**Han Ik Bae, An Na Seo,** Department of Pathology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41404, South Korea

**Author contributions:** Kang BW and Kim JG performed the majority of the study, wrote the manuscript; Lee IH, Bae HI, and Seo AN conceived the study and finalized the revision; all authors read and approved the final manuscript.

**Conflict-of-interest statement:** There is no conflict of interest in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Jong Gwang Kim, MD, PhD,** Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 807 Hogukno, Buk-gu, Daegu 41404, South Korea. jkk21c@knu.ac.kr

**Telephone:** +82-53-2003521

**Fax:** +82-53-2002029

**Received:** October 20, 2016

**Peer-review started:** October 23, 2016

**First decision:** December 20, 2016

**Revised:** February 2, 2017

**Accepted:** June 6, 2017

**Article in press:**

**Published online:**

**Abstract**

Immunotherapy has begun to revolutionize cancer treatment, by introducing therapies that target the host immune system instead of the tumor, therapies that possess unique adverse event profiles, and therapies that may cure certain types of cancer. The immune microenvironment of tumors is emerging as the most important means of understanding the relationship between a patient’ immune system and their cancer, informing prognosis, and guiding immunotherapy, such as an antibody blockade of immune checkpoints. For some solid tumors, simple quantitation of lymphocyte infiltration would seem to have prognostic significance, suggesting that lymphocyte infiltration is not passive but may actively promote or inhibit tumor growth. For gastric cancers, several studies have provided strong evidence that immune cells contribute to determining prognosis. However, the exact role of immune cells in gastric cancer remains unclear. Therefore, this review focuses on the clinical significance of immune cells, especially tumor-infiltrating lymphocytes, in gastric cancer.

**Key words**: Gastric cancer; Tumor-infiltrating lymphocytes; Immunotherapy

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Tumor-infiltrating lymphocytes (TILs) are considered a manifestation of the host immune response against tumor cells, and several studies have already reported the potential of TILs as a prognostic parameter for various human malignancies. However, only a few studies have investigated the prognostic impact of TILs in gastric cancer. Based on a comprehensive molecular characterization of gastric cancer, TILs could be a potential biomarker. Accordingly, this review focuses on the clinical significance of immune cells, especially TILs, in gastric cancer.

Kang BW, Kim JG, Lee IH, Bae HI, Seo AN. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. *World J Gastrointest Oncol* 2017; In press

**INTRODUCTION**

Gastric cancer is a major public health issue and the leading cause of cancer-related deaths. Despite numerous advances in treatment options, the prognosis for gastric cancer remains dismal, as most patients are in an advanced stage at the time of diagnosis[[1](#_ENREF_1)]. To improve the survival outcome, a better understanding of the mechanisms of disease progression is crucial, along with elucidating effective predictive or prognostic factors as therapeutic targets. Yet, while many predictive factors have already been evaluated, including clinicopathologic factors, biomarkers, genes, and microsatellite instability, their prognostic accuracies remain controversial[[2](#_ENREF_2)].

Meantime, immunotherapy has begun to revolutionize cancer treatment by introducing therapies that target the host immune system rather than the tumor, therapies that possess unique adverse event profiles, and therapies that may even cure certain types of cancer. Thus, the immune microenvironment of tumors is emerging as the most important means of understanding the relationship between a patient’ immune system and their cancer, informing prognosis, and guiding immunotherapy, such as an antibody blockade of immune checkpoints[[3](#_ENREF_3)]. For some solid tumors, simple quantitation of lymphocyte infiltration would seem to have prognostic significance, suggesting that lymphocyte infiltration is nor passive but may actively promote or inhibit tumor growth[[3](#_ENREF_3)]. For example, a meta-analysis showed a significant correlation between tumor-infiltrating lymphocytes (TILs) and clinical traits in breast cancer patients. Thus, higher value of total TILs not only predicts a neoadjuvant chemotherapy response, but also implies a better prognosis[[4](#_ENREF_4)]. For gastric cancers, several studies have provided strong evidence that immune cells contribute to determining the prognosis. It has been reported that regulatory T cells can play a role of immunosuppression and tumor progression in patients with gastric cancer, leading to a worse prognosis[[5](#_ENREF_5)]. Plus, an intratumoral high regulatory T cell/CD8+ T cell ratio has been shown as an independent predictor of a poor prognosis for gastric cancer[[6](#_ENREF_6)]. However, the exact role of immune cells in gastric cancer remains unclear. Accordingly, this review focuses on the clinical significance of immune cells, especially TILs, in gastric cancer.

**TILs IN GASTRIC CANCER**

***Cancer immunity and the role of TILs***

The evolution of cancers reflects intricate cellular and molecular interactions between tumor cells and constituents of the tumor microenvironment[[7](#_ENREF_7)]. In the first step, neoantigens created by oncogenesis are released and captured by dendritic cells for processing. Next, dendritic cells present the captured antigens on major histocompatibility class (MHC) molecules to T cells, resulting in the priming and activation of effector T cell responses against the cancer-specific antigens. Finally, the activated T cells toward to and infiltrate the tumor bed, and destroy their target cancer cells[[8](#_ENREF_8)]. These may be occurred in the tumor core, invasive margin, or adjacent tumor stroma. The functional activity of lymphoid infiltrates, such as T cells, B cells, and natural killer (NK) cells, depends upon MHC complexes or surface antigen that can be recognized specific manner. These cells can be induced to secrete different types of cytokines based on effector functions[[9](#_ENREF_9)]. Many cytokines also have the potential to enhance nonspecific inflammatory responses which by themselves may have anti-tumor activity. Plus, the potential of various cytokines to enhance both specific and innate immune responses against tumors has been demonstrated in experimental models and has been realized in clinical practice[[10](#_ENREF_10)]. Surprisingly, this process is highly regulated through various genes, such as STAT3, High-mobility group protein B1, calreticulin, and endothelial cell adhesion protein[[11](#_ENREF_11)]. Thus, TILs are incorporated into these multi-factorial interactions and their presence has proved to be a major determinant of tumor characteristics and patient outcome.

***Stromal TILs and intratumoral TILs***

Several recent studies have evaluated the prognostic and predictive importance of TILs in gastric cancer[[12](#_ENREF_12)]. TILs are the major type of infiltrating immune cells, and are represented by T cells, B cells, and NK cells. These cells can infiltrate stroma and tumor cells, and are considered a manifestation of the host immune response against tumor cells[[13](#_ENREF_13)]. Previous studies of TILs in gastric cancer have evaluated stromal and intratumoral lymphocytes separately, where a visual assessment of standard hematoxylin and eosin (H&E)-stained sections is the most commonly used approach to measure TILs[[3](#_ENREF_3),[14](#_ENREF_14)]. Based on a histopathologic analysis of TILs using H&E-stained slides, Kang *et al*[[15](#_ENREF_15)] suggested that stromal TILs can be defined as a tumor stroma area containing infiltrating mononuclear inflammatory cells, while intratumoral TILs can be defined as intraepithelial lymphocytes or mononuclear cells within tumor cells. As a result, they documented that stromal TILs can be used to predict recurrence-free survival (RFS) and disease-free survival (DFS). In contrast, another study found that increasing intratumoral TILs was significantly associated with improved cancer-specific survival (CSS)[[16](#_ENREF_16)] (Table 1). In fact, stromal TILs are well known as a superior and more reproducible parameter in breast cancer[[14](#_ENREF_14)]. Notwithstanding, there is no current consensus on the best TILs distribution for predicting survival in gastric cancer. Therefore, the methodology of interpreting TILs and cut-off values for gastric cancer needs to be standardized.

***Composition of TILs and their clinical significance***

TILs are represented by T cells, B cells, and NK cells. The subset of T cells include CD8+ cytotoxic T cells, CD4+ T helper cells, CD45RO+ memory T cells, FOXP3+ regulatory T cells, and NK cells[[12](#_ENREF_12)]. In gastric cancer, the prognostic role of each lymphocyte is summarized in the Table 2[5,17-38]. A high-density of CD3+, CD8+, and CD45RO+ cells has been strongly associated with patient survival and regional lymph node metastasis[[17](#_ENREF_17)]. Recently, Thompson *et al*[[18](#_ENREF_18)] reported that the increasing CD8+ infiltration was correlated with impaired survival and higher programmed death-ligand 1 (PD-L1) expression, indicating an adaptive immune resistance mechanism. Meanwhile, the presence of FOXP3+ regulatory T cells has been associated with both good and bad prognosis[[5](#_ENREF_5),[19-27](#_ENREF_19)]. Among the other CD4+ T cell subpopulations, a high T helper 1/T helper 2 ratio has been implicated as a favorable prognostic factor in gastric cancer[[28](#_ENREF_28)]. T helper 17 and T helper 22 cells, producers of proinflammatory interleukin, also appear to have an effect on tumor progression in gastric cancer, while high CD45RO+ memory T cells are associated with better survival of gastric cancer patients[[29](#_ENREF_29),[30](#_ENREF_30)]. Furthermore, the precise role of B cells and NK cells is currently not well defined and remains controversial[[31](#_ENREF_31),[32](#_ENREF_32)].

***Impact of TILs on subtypes of gastric cancer***

The Cancer Genome Atlas Research Network recently provided a comprehensive molecular characterization of 295 gastric cancers using various platforms, and proposed four distinct subtypes, as follows: Epstein-Barr virus (EBV)-positive tumors, microsatellite unstable tumors, genomically stable tumors, and tumors with chromosomal instability[[38](#_ENREF_38)]. Among these, EBV-positive tumors and microsatellite unstable tumors often show immune cell signaling activation. Therefore, these findings point to the possibility of TILs as prognostic and predictive markers in gastric cancer patients with EBV or mismatch repair-deficient tumors, suggesting the pivotal role of the immune mechanism in these subsets of gastric cancer. Significant correlations have also been found between microsatellite instability (MSI) and TIL positivity[[39](#_ENREF_39)]. Plus, higher densities of both CD8+ and FOXP3+ TILs have been associated with good prognosis in MSI-high gastric cancer[[22](#_ENREF_22)]. Interestingly, Chiaravalli *et al*[[34](#_ENREF_34)] reported that a high number of CD3+ and CD8+ TILs is a characteristic of gastric cancer with MSI and EBV, correlating with a favorable prognosis. In a separate study, MSI and EBV tumors showed significantly increased TILs compared with non-MSI and non-EBV tumors, and the number of TILs was significantly associated with CSS in EBV tumors[[16](#_ENREF_16)]. Meanwhile, recent data showed an independent association between high TILs and favorable RFS or DFS in 120 patients with EBV-associated gastric cancer (EBVaGC), suggesting that TILs exhibit a host cellular immune response against tumors and immunotherapy may have a potential role in patients with EBVaGC[[15](#_ENREF_15)]. Plus, although their mechanisms and effects on cancer are still unknown, previous reports have indicated that local triggering of cellular immune responses, like activated cytotoxic T cells in EBVaGC, prevents lymph node metastasis, and various molecules, such as chemokines, interleukins, intergrins, and adhesion molecules, may contribute to immune surveillance and immunogenic apoptosis[[11](#_ENREF_11),[40](#_ENREF_40)].

***Roles of programmed cell death protein in immune cells of gastric cancer***

Immune evasion is now recognized to play a key role in carcinogenesis. The strong growth potential and invasive nature of malignant tumors are at least partially attributed to the ability of the tumor cells to escape the host immune surveillance[[41](#_ENREF_41)]. In particular, the effector T-lymphocyte recognizes the tumor cell through interaction between the T-cell receptor and MHC on the tumor cell. After the immune response has been mounted, the tumor is able to express PD-L1 on its surface. The subsequent binding between PD-L1 and programmed cell death-1 (PD-1) will shut down the immune response and allow the tumor cells to escape death[[8](#_ENREF_8)]. PD-1, which belongs to the CD28 family of proteins, is a receptor expressed on a number of immune cells, including T cells, B cells, monocytes, NK cells, and dendritic cells. It has two ligands, PD-L1 and PD-L2. PD-L1 is broadly expressed[[42](#_ENREF_42)]. Several studies have already demonstrated that PD-L1 or PD-1 is highly expressed on tumor cells in gastric cancer patients[[43-46](#_ENREF_43)]. A recent study reported that 53.8% of patients were positive for PD-1 expression which was mainly restricted to TILs and 30.1% were positive for PD-L1 expression in the tumor cells, respectively[[47](#_ENREF_47)]. Although expression of PD-L1 and PD-1 in gastric cancer is closely linked to the prognosis, the results remain inconsistent[[41](#_ENREF_41)]. A recent meta-analysis by Zhang *et al*[[48](#_ENREF_48)] evaluated the prognostic value of PD-L1 in gastric cancer. Based on 1,901 patients in 10 studies, the final hazard ratio for overall-survival (OS) of 1.64 showed a significant difference in terms of PD-L1 expression (confidence interval 1.11-2.43, *P* = 0.01). Interestingly, this meta-analysis indicated that PD-L1 had no correlation with gender, age, cancer location, differentiation, depth of invasion, and tumor stage. Therefore, this study provided evidence to support benefit from targeted therapy against PD-L1 in the case of gastric cancer. Indeed, we already evaluated the tissue samples that were obtained from patients included in a previous study of EBVaGC[[15](#_ENREF_15)]. We found that intratumoral PD-L1 was significantly associated with DFS in these patients group. These observations have given rise to the hypothesis that specific inhibitors for PD-L1 or PD-1 would be potential therapeutic candidates that can affect a variety of gastric cancer.

Several therapeutic antibodies against this pathway have been developed and clinical trials are ongoing. KEYNOTE-012 was a phase 1b that evaluated pembrolizumab, a humanized IgG4 monoclonal antibody against PD-1, in patients with PD-L1-positive recurrent or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. In this trial, pembrolizumab had a 22% response rate and manageable toxicity[[49](#_ENREF_49)]. Recenly, nivolumab, a human IgG4 anti-PD-1 monoclonal antibody, has been clinically explored following the failure of standard of care. This trial (ONO-4538-12), which compared nivolumab to placebo in patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer, refractory to, or intolerant of, standard therapy, also showed a significantly prolonged OS for the nivolumab arm[[50](#_ENREF_50)]. Therefore, the success of these agents has prompted its clinical investigation in a first-line setting and clinical trials for first-line treatment are now ongoing.

**CONCLUSION**

This article summarized the association of TILs with the prognosis of gastric cancer. While TILs can be easily detected by analyzing slides of tumor sections stained with H&E, methodologic improvements are needed for more accurate determining the density and distribution of immune effectors within and around gastric cancer cells. With the development of more precise methods for analyzing immune infiltrates, it is becoming clearer that distinct infiltrating cell types have different prognostic and predictive significance. In particular, the presence of TILs may be an important biomarker for the treatment of TIL-rich tumors, such as EBV-positive or MSI-high gastric cancer, while immunotherapy including an immune checkpoint blockade can become an important part of the cancer armamentarium. Plus, specific inhibitors for PD-L1 or PD-1 would be potential therapeutic candidates that can affect a variety of gastric cancer. Therefore, understanding the effect of TILs on the natural outcome of gastric cancer will herald new opportunities for personalized therapy.

**REFERENCES**

1. **Wagner AD**, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol* 2006; **24**: 2903-2909 [PMID: 16782930 DOI: 10.1200/JCO.2005.05.0245]
2. **McLean MH**, El-Omar EM. Genetics of gastric cancer. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 664-674 [PMID: 25134511 DOI: 10.1038/nrgastro.2014.143]
3. **Fridman WH**, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer* 2012; **12**: 298-306 [PMID: 22419253 DOI: 10.1038/nrc3245]
4. **Yu X**, Zhang Z, Wang Z, Wu P, Qiu F, Huang J. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis*. Clinical and Translational Oncology* 2016; **18**: 497-506
5. **Wang B**, Xu D, Yu X, Ding T, Rao H, Zhan Y, Zheng L, Li L. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. *Ann Surg Oncol* 2011; **18**: 2585-2593 [PMID: 21347781 DOI: 10.1245/s10434-011-1609-3]
6. **Ichihara F**, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. *Clin Cancer Res* 2003; **9**: 4404-4408 [PMID: 14555512]
7. **Dunn GP**, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* 2002; **3**: 991-998 [PMID: 12407406 DOI: 10.1038/ni1102-991]
8. **Chen DS**, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity* 2013; **39**: 1-10 [PMID: 23890059 DOI: 10.1016/j.immuni.2013.07.012]
9. **Palucka AK**, Coussens LM. The Basis of Oncoimmunology. *Cell* 2016; **164**: 1233-1247 [PMID: 26967289 DOI: 10.1016/j.cell.2016.01.049]
10. **Dunn GP**, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev Immunol* 2004; **22**: 329-360 [PMID: 15032581 DOI: 10.1146/annurev.immunol.22.012703.104803]
11. **Fridman WH**, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. *Cancer Res* 2011; **71**: 5601-5605 [PMID: 21846822 DOI: 10.1158/0008-5472.CAN-11-1316]
12. **Chang WJ**, Du Y, Zhao X, Ma LY, Cao GW. Inflammation-related factors predicting prognosis of gastric cancer. *World J Gastroenterol* 2014; **20**: 4586-4596 [PMID: 24782611 DOI: 10.3748/wjg.v20.i16.4586]
13. **Balkwill F**, Mantovani A. Inflammation and cancer: back to Virchow? *The Lancet* 2001; **357**: 539-545 [DOI: 10.1016/S0140-6736(00)04046-0]
14. **Salgado R**, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol* 2015; **26**: 259-271 [PMID: 25214542 DOI: 10.1093/annonc/mdu450]
15. **Kang BW**, Seo AN, Yoon S, Bae HI, Jeon SW, Kwon OK, Chung HY, Yu W, Kang H, Kim JG. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. *Ann Oncol* 2016; **27**: 494-501 [PMID: 26673353 DOI: 10.1093/annonc/mdv610]
16. **Grogg KL**, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. *Mod Pathol* 2003; **16**: 641-651 [PMID: 12861059 DOI: 10.1097/01.MP.0000076980.73826.C0]
17. **Lee HE**, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. *Br J Cancer* 2008; **99**: 1704-1711 [PMID: 18941457 DOI: 10.1038/sj.bjc.6604738]
18. **Thompson ED**, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. *Gut* 2016 [DOI: 10.1136/gutjnl-2015-310839]
19. **Choi HS**, Ha SY, Kim HM, Ahn SM, Kang MS, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kang ES. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. *Oncotarget* 2016; **7**: 7940-7951 [PMID: 26799288]
20. **Haas M**, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. *BMC Gastroenterol* 2009; **9**: 65 [PMID: 19732435 DOI: 10.1186/1471-230X-9-65]
21. **Kim HI**, Kim H, Cho HW, Kim SY, Song KJ, Hyung WJ, Park CG, Kim CB. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. *J Surg Oncol* 2011; **104**: 728-733 [PMID: 21792941 DOI: 10.1002/jso.22038]
22. **Kim KJ**, Lee KS, Cho HJ, Kim YH, Yang HK, Kim WH, Kang GH. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. *Hum Pathol* 2014; **45**: 285-293 [PMID: 24331841 DOI: 10.1016/j.humpath.2013.09.004]
23. **Liu K**, Yang K, Wu B, Chen H, Chen X, Chen X, Jiang L, Ye F, He D, Lu Z, Xue L, Zhang W, Li Q, Zhou Z, Mo X, Hu J. Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. *Medicine* (Baltimore) 2015; **94**: e1631 [PMID: 26426650 DOI: 10.1097/MD.0000000000001631]
24. **Mizukami Y**, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. *Br J Cancer* 2008; **98**: 148-153 [PMID: 18087278 DOI: 10.1038/sj.bjc.6604149]
25. **Perrone G**, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. *Eur J Cancer* 2008; **44**: 1875-1882 [PMID: 18617393 DOI: 10.1016/j.ejca.2008.05.017]
26. **Shen Z**, Zhou S, Wang Y, Li RL, Zhong C, Liang C, Sun Y. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. *J Cancer Res Clin Oncol* 2010; **136**: 1585-1595 [PMID: 20221835 DOI: 10.1007/s00432-010-0816-9]
27. **Zhou S**, Shen Z, Wang Y, Ma H, Xu S, Qin J, Chen L, Tao H, Zhen Z, Chen G, Zhang Z, Li R, Xiao H, Zhong C, Yang Y, Liang C. CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. *PLoS One* 2013; **8**: e74430 [PMID: 24040244 DOI: 10.1371/journal.pone.0074430]
28. **Ubukata H**, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T. Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. *J Surg Oncol* 2010; **102**: 742-747 [PMID: 20872813 DOI: 10.1002/jso.21725]
29. **Liu T**, Peng L, Yu P, Zhao Y, Shi Y, Mao X, Chen W, Cheng P, Wang T, Chen N, Zhang J, Liu X, Li N, Guo G, Tong W, Zhuang Y, Zou Q. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. *J Clin Immunol* 2012; **32**: 1332-1339 [PMID: 22760549 DOI: 10.1007/s10875-012-9718-8]
30. **Wakatsuki K**, Sho M, Yamato I, Takayama T, Matsumoto S, Tanaka T, Migita K, Ito M, Hotta K, Nakajima Y. Clinical impact of tumor-infiltrating CD45RO⁺ memory T cells on human gastric cancer. *Oncol Rep* 2013; **29**: 1756-1762 [PMID: 23440298]
31. **Ishigami S**, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. *Cancer* 2000; **88**: 577-583 [PMID: 10649250]
32. **Lee K**, Hwang H, Nam KT. Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. *Gut Liver* 2014; **8**: 131-139 [PMID: 24672653 DOI: 10.5009/gnl.2014.8.2.131]
33. **Kawazoe A**, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients. *Gastric Cancer* 2017; **3**: 407-415 [DOI: 10.1007/s10120-016-0631-3]
34. **Chiaravalli AM**, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R, Novario R, Capella C. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. *Virchows Arch* 2006; **448**: 344-353 [PMID: 16261379 DOI: 10.1007/s00428-005-0066-4]
35. **Dong J**, Li J, Liu SM, Feng XY, Chen S, Chen YB, Zhang XS. CD33⁺/p-STAT1⁺ double-positive cell as a prognostic factor for stage IIIa gastric cancer. *Med Oncol* 2013; **30**: 442 [PMID: 23307253 DOI: 10.1007/s12032-012-0442-2]
36. **Rosso D**, Rigueiro MP, Kassab P, Ilias EJ, Castro OA, Novo NF, Louren**ç**o LG. [Correlation of natural killer cells with the prognosis of gastric adenocarcinoma]. *Arq Bras Cir Dig* 2012; **25**: 114-117 [PMID: 23381755 DOI: 10.1590/S0102-67202012000200011]
37. **Ishigami S**, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, Aridome K, Hokita S, Aikou T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. *Cancer letters* 2000; **159**: 103-108 [DOI: 10.1016/S0304-3835(00)00542-5]
38. **Bass AJ**, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, Weisenberger DJ, Schultz N, Shen R, Weinhold N, Kelsen DP, Bowlby R, Chu A, Kasaian K, Mungall AJ, Robertson AG, Sipahimalani P, Cherniack A, Getz G, Liu Y, Noble MS, Pedamallu C, Sougnez C, Taylor-Weiner A, Akbani R, Lee J-S, Liu W, Mills GB, Yang D, Zhang W, Pantazi A, Parfenov M, Gulley M, Piazuelo MB, Schneider BG, Kim J, Boussioutas A, Sheth M, Demchok JA, Rabkin CS, Willis JE, Ng S, Garman K, Beer DG, Pennathur A, Raphael BJ, Wu H-T, Odze R, Kim HK, Bowen J, Leraas KM, Lichtenberg TM, Weaver S, McLellan M, Wiznerowicz M, Sakai R, Getz G, Sougnez C, Lawrence MS, Cibulskis K, Lichtenstein L, Fisher S, Gabriel SB, Lander ES, Ding L, Niu B, Ally A, Balasundaram M, Birol I, Bowlby R, Brooks D, Butterfield YSN, Carlsen R, Chu A, Chu J, Chuah E, Chun H-JE, Clarke A, Dhalla N, Guin R, Holt RA, Jones SJM, Kasaian K, Lee D, Li HA, Lim E, Ma Y, Marra MA, Mayo M, Moore RA, Mungall AJ, Mungall KL, Nip KM, Robertson AG, Schein JE, Sipahimalani P, Tam A, Thiessen N, Beroukhim R, Carter SL, Cherniack AD, Cho J, Cibulskis K, DiCara D, Frazer S, Fisher S, Gabriel SB, Gehlenborg N, Heiman DI, Jung J, Kim J, Lander ES, Lawrence MS, Lichtenstein L, Lin P, Meyerson M, Ojesina AI, Pedamallu CS, Saksena G, Schumacher SE, Sougnez C, Stojanov P, Tabak B, Taylor-Weiner A, Voet D, Rosenberg M, Zack TI, Zhang H, Zou L, Protopopov A, Santoso N, Parfenov M, Lee S, Zhang J, Mahadeshwar HS, Tang J, Ren X, Seth S, Yang L, Xu AW, Song X, Pantazi A, Xi R, Bristow CA, Hadjipanayis A, Seidman J, Chin L, Park PJ, Kucherlapati R, Akbani R, Ling S, Liu W, Rao A, Weinstein JN, Kim S-B, Lee J-S, Lu Y, Mills G, Laird PW, Hinoue T, Weisenberger DJ, Bootwalla MS, Lai PH, Shen H, Triche T, Van Den Berg DJ, Baylin SB, Herman JG, Getz G, Chin L, Liu Y, Murray BA, Noble MS, Askoy BA, Ciriello G, Dresdner G, Gao J, Gross B, Jacobsen A, Lee W, Ramirez R, Sander C, Schultz N, Senbabaoglu Y, Sinha R, Sumer SO, Sun Y, Weinhold N, Thorsson V, Bernard B, Iype L, Kramer RW, Kreisberg R, Miller M, Reynolds SM, Rovira H, Tasman N, Shmulevich I, Ng SCS, Haussler D, Stuart JM, Akbani R, Ling S, Liu W, Rao A, Weinstein JN, Verhaak RGW, Mills GB, Leiserson MDM, Raphael BJ, Wu H-T, Taylor BS, Black AD, Bowen J, Carney JA, Gastier-Foster JM, Helsel C, Leraas KM, Lichtenberg TM, McAllister C, Ramirez NC, Tabler TR, Wise L, Zmuda E, Penny R, Crain D, Gardner J, Lau K, Curely E, Mallery D, Morris S, Paulauskis J, Shelton T, Shelton C, Sherman M, Benz C, Lee J-H, Fedosenko K, Manikhas G, Potapova O, Voronina O, Belyaev S, Dolzhansky O, Rathmell WK, Brzezinski J, Ibbs M, Korski K, Kycler W, ŁaŸniak R, Leporowska E, Mackiewicz A, Murawa D, Murawa P, Spychała A, Suchorska WM, Tatka H, Teresiak M, Wiznerowicz M, Abdel-Misih R, Bennett J, Brown J, Iacocca M, Rabeno B, Kwon S-Y, Penny R, Gardner J, Kemkes A, Mallery D, Morris S, Shelton T, Shelton C, Curley E, Alexopoulou I, Engel J, Bartlett J, Albert M, Park D-Y, Dhir R, Luketich J, Landreneau R, Janjigian YY, Kelsen DP, Cho E, Ladanyi M, Tang L, McCall SJ, Park YS, Cheong J-H, Ajani J, Camargo MC, Alonso S, Ayala B, Jensen MA, Pihl T, Raman R, Walton J, Wan Y, Demchok JA, Eley G, Mills Shaw KR, Sheth M, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Davidsen T, Hutter CM, Sofia HJ, Burton R, Chudamani S, Liu J. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID:25079317 DOI: 10.1038/nature13480]
39. **Giampieri R**, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, Bittoni A, Bianconi M, Scarpelli M, Bracci R, Scartozzi M, Cascinu S. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. *Gastric Cancer*2017; **20**: 156-163 [PMID: 26796888 DOI: [10.1007/s10120-016-0594-4](https://doi.org/10.1007/s10120-016-0594-4)]
40. **van Beek J zHA**, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM, Meijer CJ, Bloemena E. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. *Am J Surg Pathol* 2006; **30**: 59-65 [DOI: 10.1097/01.pas.0000176428.06629.1e]
41. **Liu X**, Yang Z, Latchoumanin O, Qiao L. Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. *Therap Adv Gastroenterol* 2016; **9**: 853-860 [PMID: 27803740 DOI: 10.1177/1756283X16658251]
42. **Park J**, Kwon M, Shin EC. Immune checkpoint inhibitors for cancer treatment. *Arch Pharm Res* 2016; **39**: 1577-1587 [PMID: 27770382 DOI: 10.1007/s12272-016-0850-5]
43. **Zhang L**, Qiu M, Jin Y, Ji J, Li B, Wang X, Yan S, Xu R, Yang D. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. *Int J Clin Exp Pathol* 2015; **8**: 11084-11091 [PMID: 26617827]
44. **Wu C**, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. *Acta Histochem* 2006; **108**: 19-24 [PMID: 16530813 DOI: 10.1016/j.acthis.2006.01.003]
45. **Takaya S**, Saito H, Ikeguchi M. Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery. *Yonago Acta Med* 2015; **58**: 39-44 [PMID: 26190896]
46. **Raufi AG**, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. *J Gastrointest Oncol* 2015; **6**: 561-569 [PMID: 26487950]
47. **Böger C**, Behrens H-M, Mathiak M, Krüger S, Kalthoff H, Röcken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. *Oncotarget* 2016; **7**: 24269-24283 [DOI: 10.18632/oncotarget.8169]
48. **Zhang M**, Dong Y, Liu H, Wang Y, Zhao S, Xuan Q, Wang Y, Zhang Q. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. *Sci Rep* 2016; **6**: 37933 [PMID: 27892511 DOI: 10.1038/srep37933]
49. **Muro K**, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin C-C, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang Y-J. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. *The Lancet Oncology* 2016; **17**: 717-726 [DOI: 10.1016/S1470-2045(16)00175-3]
50. **Kang YK**, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yoshikawa T, Oh SC, Tamura T, Lee KW, Boku N, Chen LT. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. *J Clin Oncol* 2017; **35** suppl 4S: abstract 2

**P-Reviewer:** Aoyagi K, Deans C **S-Editor:** Kong JX **L-Editor: E-Editor:**

**Specialty type:** Oncology

**Country of origin:** South Korea

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Tumor-infiltrating lymphocytes associated with the prognosis of gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | Sample size | Patient group | Location | Criteria (Cut-off) | Prognostic role |
| Kang *et al*[[15](#_ENREF_15)]Grogg *et al*[[16](#_ENREF_16)]Lee *et al*[[17](#_ENREF_17)] | 120110220 | EBVaGCGG | StromalIntratumoralIntratumoral | High infiltrationHigh infiltrationHigh density | Decreased DFS and RFSIncreased CSSIncreased OS |

TILs: Tumor-infiltrating lymphocytes; EBVaGC: Epstein-Barr virus-associated gastric cancer; DFS: Disease-free survival; RFS: Recurrence-free survival; G: Gastric cancer; CSS: Cancer-specific survival; OS: Overall-survival.

**Table 2 Lymphocyte subtypes associated with the prognosis of gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | Lymphocyte subtypes | Sample size | Patient group | Criteria (Cut-off) | Prognostic role |
| Lee *et al*[[17](#_ENREF_17)] | CD3+, CD8+, CD45RO+ | 220 | G | High density | Increased OS |
| Thompson *et al*[[18](#_ENREF_18)] | CD8+ | 43 | G/GEJ | High density | Decreased PFS and OS |
| Kawazoe *et al*[[33](#_ENREF_33)] | CD8+ | 487 | G | High density | Increased OS |
| Wakatsuki *et al*[[30](#_ENREF_30)]  | CD45RO+ | 101 | G | High numbers | Increased PFS and OS |
| Chiaravalli *et al*[[34](#_ENREF_34)]  | CD3+, CD8+ | 96 | MSI –H G | High numbers | Increased OS |
| Kim *et al*[[22](#_ENREF_22)] | CD8+, FOXP3+ | 99 | MSI –H G | High density | Increased OS |
| Liu *et al*[[23](#_ENREF_23)] | CD8+/ FOXP3+ ratio | 166 | G | High ratio | Increased OS |
| Shen *et al*[[26](#_ENREF_26)] | FOXP3+/CD8+ ratio | 133 | G | High ratio | Decreased OS |
| Wang *et al*[[5](#_ENREF_5)] | FOXP3+ | 107 | G | High expression | Increased OS |
| Haas *et al*[[20](#_ENREF_20)]Mizukami *et al*[[24](#_ENREF_24)]  | FOXP3+FOXP3+ | 52120 | GG | High numbersDiffuse pattern | Increased OSDecreased OS |
| Perrone *et al*[[25](#_ENREF_25)]  | FOXP3+ | 110 | G | High numbers | Decreased RFS and OS |
| Zhou *et al*[[27](#_ENREF_27)]  | FOXP3+ | 133 | G | High numbers | Decreased OS |
| Choi *et al*[[19](#_ENREF_19)] | FOXP3+/CD4+ ratio | 28 | G | High ratio | Increased OS |
| Kim *et al*[[21](#_ENREF_21)] | FOXP3+/CD4+ ratio | 180 | G | High ratio | Decreased OS |
| Dong *et al*[[35](#_ENREF_35)] | CD20+ | 100 | G | High density | Increased OS |
| Ishigami *et al*[[31](#_ENREF_31)] | NK cells | 146 | G | High numbers | Increased OS |
| Rosso *et al*[[36](#_ENREF_36)] | NK cells | 72 | G | High concentration | Increased DFS and OS |
| Ishigami *et al*[[37](#_ENREF_37)] | NK cells | 169 | G | High numbers | Increased OS |
| Ubukata *et al*[[28](#_ENREF_28)] | Th1/Th2 ratio | 157 | G | High ratio1 | Increased OS |
| Liu *et al*[[29](#_ENREF_29)] | Th22, Th17 | 32 | G | High numbers1 | Decreased OS |

1Peripheral blood. G: Gastric cancer; OS: Overall-survival; G/GEJ: Gastric/gastro-esophageal junction cancer; PFS: Progression-free survival; MSI-H: Microsatellite instability-high; RFS: Relapse-free survival; DFS: Disease-free survival.